1. Home
  2. AYTU vs IRIX Comparison

AYTU vs IRIX Comparison

Compare AYTU & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • IRIX
  • Stock Information
  • Founded
  • AYTU N/A
  • IRIX 1989
  • Country
  • AYTU United States
  • IRIX United States
  • Employees
  • AYTU N/A
  • IRIX N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • AYTU Health Care
  • IRIX Health Care
  • Exchange
  • AYTU Nasdaq
  • IRIX Nasdaq
  • Market Cap
  • AYTU 23.0M
  • IRIX 20.2M
  • IPO Year
  • AYTU N/A
  • IRIX 1996
  • Fundamental
  • Price
  • AYTU $2.10
  • IRIX $0.89
  • Analyst Decision
  • AYTU Strong Buy
  • IRIX
  • Analyst Count
  • AYTU 3
  • IRIX 0
  • Target Price
  • AYTU $9.17
  • IRIX N/A
  • AVG Volume (30 Days)
  • AYTU 62.6K
  • IRIX 81.4K
  • Earning Date
  • AYTU 11-13-2025
  • IRIX 11-11-2025
  • Dividend Yield
  • AYTU N/A
  • IRIX N/A
  • EPS Growth
  • AYTU N/A
  • IRIX N/A
  • EPS
  • AYTU N/A
  • IRIX N/A
  • Revenue
  • AYTU $66,382,000.00
  • IRIX $50,647,000.00
  • Revenue This Year
  • AYTU N/A
  • IRIX $9.61
  • Revenue Next Year
  • AYTU $29.12
  • IRIX N/A
  • P/E Ratio
  • AYTU N/A
  • IRIX N/A
  • Revenue Growth
  • AYTU 1.84
  • IRIX 4.58
  • 52 Week Low
  • AYTU $0.95
  • IRIX $0.78
  • 52 Week High
  • AYTU $2.82
  • IRIX $1.95
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 41.10
  • IRIX 34.73
  • Support Level
  • AYTU $2.01
  • IRIX $1.00
  • Resistance Level
  • AYTU $2.18
  • IRIX $1.19
  • Average True Range (ATR)
  • AYTU 0.13
  • IRIX 0.05
  • MACD
  • AYTU -0.02
  • IRIX -0.01
  • Stochastic Oscillator
  • AYTU 50.98
  • IRIX 5.79

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

About IRIX IRIDEX Corporation

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Share on Social Networks: